GROWTH AND STRONG FINANCIAL POSITION JANUARY – JUNE 2014 · Net sales increase and total SEK 694.8 (684.4) million · Operating profit (EBIT) of SEK 66.3 (71.1) million; operating margin of 9.5 per cent · Pre-tax profit of SEK 66.6 (71.3) million · Profit after tax of SEK 51.5 (54.1) million · Earnings per share of SEK 0.98 (1.02) · Cash flow from operations of SEK 53.5 (69.8) million · Liquid assets of SEK 119.8 million APRIL – JUNE 2014 · Net sales increase and total SEK 346.2 (344.1) million · Operating profit (EBIT) of SEK 30.3 (36.8) million; operating margin of 8.7 per cent · Pre-tax profit of SEK 30.6 (37.0) million · Profit after tax of SEK 23.7 (28.9) million · Earnings per share of SEK 0.45 (0.55) · Cash flow from operations of SEK 30.3 (41.4) million SIGNIFICANT EVENTS DURING THE FIRST HALF OF 2014 · Annual General Meeting decides on a shareholders’ dividend of SEK 2.60 per share, approximately SEK 137 million · HiQ wins business-critical assignment and becomes strategic partner to Finnair · HiQ creates an innovative mobile service that helps the Gothenburg Symphony Orchestra to spread their concerts worldwide · HiQ is named partner to the Finnish Customs, with the task to ensure smooth transportation of goods · HiQ wins business-critical assignments for SAS and becomes strategic partner to the airline company · HiQ helps Volvo Cars with the technology for Roam Delivery, which allows customers to have goods delivered straight to the trunk of their connected car · HiQ creates “Facebook for deafblind people” for The Swedish Post and Telecom Authority · HiQ becomes digital partner to Stena Match Cup Sweden and boosts the event’s digital communication · HiQ wins assignment for Varma, the leader within earnings-related pension in Finland · HiQ develops the mobile bank solution S-mobiili for the Finnish S Group · HiQ wins framework agreement with Systembolaget · HiQ wins framework agreement with The Federation of Swedish Farmers and creates digital learning aids for middle school children · HiQ wins framework agreement with a leading industrial company concerning software development · HiQ improves Elektroautomatik’s digital presence and communication FOR FURTHER INFORMATION, PLEASE CONTACT: Lars Stugemo, CEO and President of HiQ, tel. +46 (0)8-588 90 000 Laura Manninen, Acting Head of Corporate Communications, HiQ, tel. +46 (0)734 -481 317 HiQ is required by Swedish law (the Securities Market Act and/or the Financial Instruments Trading Act) to publish the information in this interim report. This report was made public at 07:30 (CET) on 12 August 2014. HiQ simplifies and improves people’s lives through solutions within communications and software development. The company is a leader in these areas and has the Nordic region as its home market. HiQ employs more than 1,300 staff and has offices both in the Nordic countries and in Russia. HiQ is listed on the NASDAQ OMX Stockholm Mid Cap List. For more information, please visit www.hiq.se
INTERIM REPORT JANUARY – JUNE 2014 GROWTH AND STRONG
Top 10 Most Recent News Articles
Voter Events by Valley Community Healthcare Aim to Empower
Here's a game-changer for the community. Valley Community Healthcare (VCH) is stepping up, proving that healthcare doesn't just stick to check-ups and prescriptions. It's about the whole shebang—community empowerment included. This October, VCH is hosting two incredible voter events, collaborating with the Los Angeles County Registrar-Recorder's Mobile Voting Program....
Continue Reading
Weifang's Cultural Resurgence: A Global Epigraphy Fest
A Historical Meltdown into Global Recognition Welcome to the ride where ancient stones talk and cultural borders vanish. We're diving into the beating heart of Weifang, a place you're probably hearing about now because the town's hosting a packed international media tour. And, for a change, this isn't just another tourist trap; it's a cultural adrenaline shot to the arm,...
Continue Reading
AEVEX Facing Class Action Deadline Amid Stock Turmoil
Investors are no strangers to the rough and tumble of stock markets, but things get downright messy when trust is shattered. That's the sorry saga unfolding with AEVEX, where shareholders are feeling the heat after a sharp nosedive in stock value. The clock is ticking to join the class action, and any AEVEX investor worth their salt should pay attention. Unraveling...
Continue Reading
Masimo's smartSET™ Revolutionizes Patient Monitoring
Breaking Ground in Patient Monitoring Let's dive into the gritty details behind Masimo's latest FDA-nod: the smartSET™ system. This gizmo ain't your ordinary pulse oximeter; it's a next-gen hand-holder for the medical world, poised to ride the AI wave straight into the clinic. They've cracked open a new way for clinicians to peek behind the curtain of patient vitals,...
Continue Reading
LG OLED evo W6: UAE Roadshow Starts with a Bang
They've done it again, folks. LG Electronics is out there kicking up a storm with their all-new OLED evo W6 True Wireless Wallpaper TV, and they're bringing the action straight to the UAE's doorsteps. Imagine taking a stroll and stumbling upon this technological marvel at some fancy spot like The Lotus Lounge at Anantara The Palm Dubai Resort. This ain't just a TV, it's a...
Continue Reading
Innventure Faces Major Lawsuit Over Misleading Investors
Missteps at Innventure: A Costly Lesson in Investor Trust The stock market is no stranger to drama, but Innventure's saga feels like a page ripped right out of a thriller novel. You’ve got accusations, alleged fabrications, and a swift drop in stock prices that’s left some investors shaking their heads. The company, nestled under the ticker NASDAQ:INV, finds itself...
Continue Reading
Hyliion Class Action Deadline Nears for Investors
Potential Shockwaves for Hyliion Investors Investors are having a showdown with Hyliion (NYSE:HYLN) these days. With the looming October 27, 2026, deadline to jump into a securities class action, it seems Hyliion's latest escapade smells worse than a fish market on a hot day. We’ve got allegations here stronger than your uncle’s morning coffee. Understanding the Legal...
Continue ReadingTop 5 Most Recently Viewed Articles
Cemtrex's Stock Surge Sparks Interest in Leading Movers
Cemtrex Experiences Notable Share Surge Shares of Cemtrex, Inc. CETX have seen a significant uptick amid pre-market trading. This boost comes on the heels of better-than-expected sales in the latest quarter, reporting an impressive $18.10 million in sales, surpassing the general analyst expectation of $16.39 million. This remarkable performance in sales has sparked...
Continue Reading
Exciting New PharmD-MBA Pathway Combines Pharmacy and Business
Collaboration between Cal Poly Pomona and Western University In an exciting move, Cal Poly Pomona's Singelyn Graduate School of Business and Western University of Health Sciences have teamed up to create a groundbreaking pathway for aspiring healthcare professionals. This innovative PharmD-MBA program combines the fields of pharmacy and business, providing a unique...
Continue Reading
Kaskela Law Investigates Stock Misconduct in Stanley Black & Decker
Overview of the Investigation by Kaskela Law LLC Kaskela Law LLC has announced an important investigation focused on Stanley Black & Decker, Inc. (NYSE: SWK) concerning allegations of potential securities fraud. This inquiry is primarily aimed at safeguarding the interests of long-term investors who hold shares in this well-known manufacturing company. Details Surrounding...
Continue Reading
Legend Biotech's Carvykti: A Leading Force in Cancer Treatment
Redburn's Positive Outlook for Legend Biotech Recently, Redburn-Atlantic began covering Legend Biotech Corp. (NASDAQ: LEGN) with a favorable Buy rating and set a price target of $86.00 for the stock. This biotechnology company has made significant strides, particularly with the recent approval of its innovative product, Carvykti, designed for the treatment of multiple...
Continue Reading
Transforming the Anti-Obesity Drug Market for Future Success
Global Anti-Obesity Drug Market Overview As global health concerns rise, the demand for anti-obesity drugs is surging. Recent reports estimate that the anti-obesity drug market will soar to USD 82.55 billion in the coming years. This impressive growth, fueled by an anticipated compound annual growth rate (CAGR) of 18.01%, signals a crucial moment for pharmaceutical...
Continue Reading